Vanguard Capital Management
WHWK

Vanguard Capital Management’s Whitehawk Therapeutics WHWK Stock Holding History

Vanguard Capital Management’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.36M Buy
1,388,561
+72,791
+6% +$303K ﹤0.01% 3030
2026
Q1 		$4.54M Buy
+1,315,770
New +$4.12M ﹤0.01% 3100

Other funds holding WHWK

YF
Yu Fan $108M AUM 137.54% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $136M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vanguard Capital Management's WHWK Position: Q2 2026 in Review

Vanguard Capital Management increased its Whitehawk Therapeutics (WHWK) stake by 5.5% in Q2 2026, buying an estimated $303K and bringing the position to 1,388,561 shares worth $6.36M. The position accounts for ﹤0.01% of the portfolio, ranked #3030.

Vanguard Capital Management first reported a position in WHWK in Q1 2026 and has held it in 2 quarters since. 78 funds tracked by Wall St. Rank hold WHWK as of Q2 2026.

  • Vanguard Capital Management held 1,388,561 shares of Whitehawk Therapeutics worth $6.36M as of Q2 2026.
  • Vanguard Capital Management bought 72,791 Whitehawk Therapeutics shares in Q2 2026, an estimated $303K.
  • Whitehawk Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3030 holding.
  • Vanguard Capital Management first reported a position in Whitehawk Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 78 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.